• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Inhibition of Influenza Entry by Organosilicon Compounds

tetano

Editor, Senior Moderator
J Med Virol


. 2025 Jun;97(6):e70436.
doi: 10.1002/jmv.70436. Inhibition of Influenza Entry by Organosilicon Compounds

Aleksandar Antanasijevic[SUP] 1 2 [/SUP], Nicholas J Haferman[SUP] 3 [/SUP], Amir Shimon[SUP] 1 [/SUP], Smanla Tundup[SUP] 4 [/SUP], Varada Anirudhan[SUP] 5 [/SUP], Lijun Rong[SUP] 5 [/SUP], Balaji Manicassamy[SUP] 4 [/SUP], Duncan Wardrop[SUP] 3 [/SUP], Michael Caffrey[SUP] 1 [/SUP]



Affiliations
Abstract

Hemagglutinin (HA) plays a critical role in the entry of influenza and thus HA is a target for the development of entry inhibitors as antivirals. One of the first small molecule inhibitors of influenza entry to be described was tert-butylhydroquinone (TBHQ), a commonly used antioxidant. This compound was shown to inhibit influenza containing Group 2 HA, such as H3 and H7 HA circulating in humans and avians. One limitation of TBHQ is the propensity to oxidize in solution, resulting in a less active form of the compound. Recently, our group has shown that the reactivity of TBHQ may be significantly reduced through substitution of one hydroxyl group with a methoxy, resulting in a concurrent increase in potency and a decrease in cytotoxicity. In this study, we demonstrate that the inhibitory capacity can be further improved by introducing tri-methyl silane (TMS) in place of the tert-butyl (TB) group. Silicon-based derivatives of TBHQ exhibited increased stability in solution compared to the parent TBHQ compound. Analysis using NMR spectroscopy revealed similar interaction patterns for the original and engineered compounds, although the TMS group was creating stronger hydrophobic contacts within the binding pocket on HA. Strikingly, TMS-containing compounds exhibited increased in vitro activity against pseudotyped and live influenza viruses carrying Group 2 HAs. In summary, we applied a novel strategy for chemical optimization of antiviral compounds and demonstrated that this approach can improve their stability and their potency for the target protein.

Keywords: antiviral agents; hemagglutinin; infection; influenza virus; virus classification.

 
Back
Top Bottom